Latest KFF Health News Stories
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
Qué son los medicamentos compuestos que millones de personas usan para bajar de peso
La FDA permite e incluso fomenta que las farmacias de compuestos produzcan y vendan copias cuando un medicamento está en escasez, como es el caso de las drogas para combatir el sobrepeso y la obesidad.
1st Biden-Trump Debate of 2024: What They Got Wrong, and Right
A debate marked by President Joe Biden’s faltering performance featured clashes over insulin costs, inflation, abortion, immigration, and Jan. 6.
KFF Health News' 'What the Health?': SCOTUS Rejects Abortion Pill Challenge — For Now
The Supreme Court has dismissed a challenge to the FDA’s approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of KFF Health News, and Emmarie Huetteman of KFF Health News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF president and CEO Drew Altman about KFF’s new “Health Policy 101” primer.
Weight-Loss Drugs Are So Popular They’re Headed for Medicare Negotiations
The steep prices — and popularity — of Ozempic and similar weight-loss and diabetes drugs could soon make them a priority for Medicare drug price negotiations. List prices for a month’s supply of the drugs range from $936 to $1,349, according to the Peterson-KFF Health System Tracker. The Inflation Reduction Act President Biden signed in […]
Journalists Talk Cost of Weight Loss Drugs and Lack of Obesity Doctors to Manage Their Use
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss topical stories. Here’s a collection of their appearances.
High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
Personas de bajos ingresos no pueden recibir terapias efectivas contra la diabetes por el alto costo
La escasez de suministros y las barreras que ponen las aseguradoras para obtener esta poderosa clase de medicamentos, llamados agonistas de GLP-1, han dejado a muchas personas que viven con diabetes y obesidad sin los medicamentos que necesitan para mantenerse saludables.
Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.
KFF Health News' 'What the Health?': Abortion Access Changing Again in Florida and Arizona
A six-week abortion ban took effect in Florida this week, dramatically restricting access to the procedure not just in the nation’s third-most-populous state but across the South. Patients from states with even more restrictive bans had been flooding in since the overturn of Roe v. Wade in 2022. Meanwhile, the CEO of the health behemoth UnitedHealth Group appeared before committees in both the House and Senate, where lawmakers grilled him about the February cyberattack on subsidiary Change Healthcare and how its ramifications are being felt months later. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachana Pradhan of KFF Health News join KFF Health News’ Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
This State Isn’t Waiting for Biden To Negotiate Drug Prices
As the federal government negotiates with drugmakers to lower the price of 10 expensive drugs for Medicare patients, impatient legislators in some states are trying to go even further. Leading the pack is Colorado, where a new Prescription Drug Affordability Review Board is set to recommend an “upper payment limit” for drugs it deems unaffordable. In late […]
A Paramedic Was Skeptical About This Rx for Stopping Repeat Opioid Overdoses. Then He Saw It Help.
For years, addiction response teams have traveled around Florida to connect people who have overdosed with resources and recovery centers. Now, a handful have a new tool in their kit: buprenorphine, which can help prevent the cravings and withdrawal symptoms that lead to more drug use.
KFF Health News' 'What the Health?': The ACA Turns 14
Saturday marks the 14th anniversary of the still somewhat embattled Affordable Care Act. Health and Human Services Secretary Xavier Becerra joins host Julie Rovner to discuss the accomplishments of the health law — and the challenges it still faces. Also this week, Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Mary Agnes Carey of KFF Health News join Rovner to discuss what should be the final funding bill for HHS for fiscal 2024, next week’s Supreme Court oral arguments in a case challenging abortion medication, and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
Biden Said Medicare Drug Price Negotiations Cut the Deficit by $160B. That’s Years Away.
Savings estimated by the Congressional Budget Office from allowing the federal government to negotiate Medicare drug prices are based on a 10-year cumulative projection.
A Battle Between Drugmakers and Insurers Hits Patients in the Wallet
There’s a long-running battle between insurers and drugmakers over financial assistance programs that purport to help patients afford expensive drugs. And lately, insurers have been losing ground as lawmakers, regulators and courts weigh in. The issue is whether coupons and other copay aid many patients get from drugmakers should count toward annual insurance deductibles and […]
Watch: Many Americans Are Unaware of HIV Prevention Medication
Some Americans mistakenly believe medication to prevent HIV transmission through sex is just for certain groups such as gay men, but anyone who’s at risk for contracting HIV through sex could benefit.
Colorado Isn’t Giving up on Its Drug Importation Dream
Colorado hopes to join Florida to become only the second state authorized to import prescription drugs from Canada. But they’re hitting the same hurdles: drugmakers — and the FDA. Colorado officials recently amended their 2022 importation application with the Food and Drug Administration, in the process revealing new correspondence that shows the state’s so-far fruitless […]
KFF Health News' 'What the Health?': The State of the Union Is … Busy
At last, Congress is getting half of its annual spending bills across the finish line, albeit five months after the start of the fiscal year. Meanwhile, President Joe Biden delivers his annual State of the Union address, an over-the-counter birth control pill is (finally) available, and controversy erupts over new public health guidelines for covid-19 isolation. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Neera Tanden, the White House domestic policy adviser, about Biden’s health agenda. Plus, for “extra credit,” the panelists suggest health policy stories they read this week that they think you should read, too.
Biden Is Right. The US Generally Pays Double That of Other Countries for Rx Drugs.
Research has consistently found that, overall, U.S. prescription drug prices are significantly higher, sometimes two to four times as high, compared with prices in other high-income industrialized countries. However, some market factors can obscure actual prices, making comparisons harder.
America Worries About Health Costs — And Voters Want to Hear From Biden and Republicans
The presidential election is likely to turn on the simple question of whether Americans want Donald Trump back in the White House. But health care tops the list of household financial worries for adults from both parties.
